share_log

同源康医药-B(02410.HK)中期研发成本1.38亿元 同比增加15.3%

Tongyuan Kang Pharmaceutical-B (02410.HK) mid-term R&D costs increased by 0.138 billion yuan, a year-on-year increase of 15.3%.

Gelonghui Finance ·  Aug 30 17:26

Gelonghui, August 30th | Tongyuan Kangyao-B (02410.HK) announced that in the six months ending June 30, 2024 and June 30, 2023, the group did not generate any revenue. The research and development costs during this period amounted to RMB 137,758,000, an increase of 15.3% year-on-year. This increase is mainly attributed to the increase in experimental and testing expenses, especially those related to the development of core products.

The loss for the reporting period increased by 26.3% from RMB 173,849,000 for the six months ending June 30, 2023 to RMB 219,533,000 for the six months ending June 30, 2024.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment